PHAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Phathom Pharmaceuticals Inc (PHAT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts, such as analyst upgrades and revenue growth, the overbought RSI, lack of recent trading signals, and negative financial performance trends suggest waiting for a better entry point.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 85.001, signaling an overbought condition. The stock is trading near its resistance levels (R1: 12.396, R2: 13), which may limit immediate upside potential.
Potential positive catalysts from weekly prescription data.
The RSI indicates overbought conditions, and the stock is near resistance levels. No significant hedge fund or insider trading activity. No recent news or congress trading data.
In Q4 2025, revenue increased significantly by 94.12% YoY to $57.58M. However, net income dropped to -$21.15M (-71.59% YoY), and EPS fell to -0.29 (-72.38% YoY). Gross margin slightly decreased to 86.72% (-0.48% YoY).
Barclays upgraded PHAT to Overweight with a price target of $18, citing an attractive entry point and potential revenue ramp. Guggenheim raised its price target to $25, encouraged by the company's profitability goals for early Q3 2026. Goldman Sachs raised its price target to $13 but maintained a Neutral rating due to uncertainties around marketing campaigns and regulatory exclusivity.
